ImaginAb is an immune and oncology imaging company developing a pipeline of novel products that give physicians unprecedented insights into the patient’s health—enabling better patient selection and treatment monitoring for immuno-oncology therapies and other drugs.

Harnessing the specificity of monoclonal antibodies, ImaginAb engineers small, highly targeted proteins known as minibodies that image important molecular targets using standard Positron Emission Tomography (PET).

Our imaging tools help physicians answer important clinical questions, improving the path of care and ultimately helping patients live longer, healthier lives.

   

Latest News

ImaginAb, Inc. CEO, Martyn Coombs, and CBO, Ivan Plavec to Be In Japan to Discuss Clinical Collaborations in Immuno-oncology

ImaginAb Announces Collaboration with Merck for CD8 T cell I/O Imaging Agent

ImaginAb would like to congratulate Dr. James P. Allison, a member of its Scientific Advisory Board, on winning the Nobel Prize in Medicine. This is a well-deserved achievement earned through immense contribution to science, medicine, and patients.

ImaginAb and CPDC Announce Clinical Trial Supply Manufacture and Distribution Agreement for ImaginAb’s CD8 Immuno PET Tracer

ImaginAb Appoints James Allison, Padmanee Sharma and Ramy Ibrahim to Scientific Advisory Board

ImaginAb Reconstitutes Japanese Subsidiary

Martyn Coombs, CEO of ImaginAb, Presenting at SNMMI 2018

CD4 Imaging of Inflammation

ImaginAb Reconstitutes Scientific Advisory Board

ImaginAb Appoints Ian Wilson as Chief Operating Officer 

ImaginAb Closes $8 million New Funding to Accelerate Clinical Development of CD8 ImmunoPET Agent

ImaginAb Inc. Announces Strategic Collaboration with Boehringer Ingelheim to Develop New Technology for Monitoring Anti-tumor Activity of the Immune System

ImaginAb Appoints Martyn Coombs as New Chief Executive Officer

Featured Publications

ImaginAb presented poster at AACR 2016 on sensitivity of 89Zr-labeled anti-CD8 minibody  for PET imaging of infiltrating CD8+ T cells

PET Imaging of Cytotoxic Human T cells Using an 89Zr-Labeled Anti-CD8 Minibody

Optimization of Desferrioxamine Conjugation to a Cytotoxic ADC for In Vivo PET Imaging Studies